Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/biology-technology-1/calbiotech-awarded-u-s--army-phase-i-sbir-research-contract-to-develop-analyte-specific-reagents-for-the-diagnosis-of-dengue-fever-virus-14750-2/;/a></li><li><a) was not found.

Search biology technology 1 calbiotech awarded u s army phase i sbir research contract to develop analyte specific reagents for the diagnosis of dengue fever virus 14750 2 ; a>< li><li><a at Google

Search biology technology 1 calbiotech awarded u s army phase i sbir research contract to develop analyte specific reagents for the diagnosis of dengue fever virus 14750 2 ; a>< li><li><a at Yahoo

Search biology technology 1 calbiotech awarded u s army phase i sbir research contract to develop analyte specific reagents for the diagnosis of dengue fever virus 14750 2 ; a>< li><li><a at Msn

Google
 
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2Successful stem cell therapy for treatment of eye disease 2IGC scientist receives prestigious EMBO installation grant 2Orphanage Receives Nearly 241 Million from Private Donor 53804 1Orphanage Receives Nearly 241 Million from Private Donor 53804 2Orphanage Receives Nearly 241 Million from Private Donor 53804 3SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 1SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 2SDSU 26apos 3Bs Process Improvement Programs Help Businesses Achieve Bottom Line Results 53801 3Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 1Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 2Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 3Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 4Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 5Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 6Cell Therapeutics Second Quarter Net Loss Decreases 54 25 3B Pixantrone NDA Submitted to the FDA for Approval 13406 7
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4